

# Non-cGMP API Starting Materials + Non-cGMP API Pilot Plant - Asset Opportunity

## Non-cGMP API Drug Development Starting Materials + API Pilot Plant and cGMP CDMO: Ready for Immediate Acquisition

- + Privately-owned Active Pharmaceutical Ingredient (API) company developing and manufacturing complex API's, with deep expertise in Medicinal Chemistry and Drug Discovery.
- + Leadership Team with diverse industry experience across both facilities in India and North America.
- + 2021 Revenue of \$31-34 Million, with a 61% EBITDA, delivering \$20 Million bottom line.
- + 9,100 ft<sup>2</sup> facility with R&D labs and newly constructed cGMP Suite in USA.
- + 48,000 ft<sup>2</sup> R&D labs, non-GMP Pilot and Manufacturing Plants for pre-clinical material and 37,000 ft<sup>2</sup> for expansion in India.
- + This company serves a client base which includes publicly listed US biotech companies and big pharma based in Asia-Pacific.
- + 110 FTEs, with 10 PhD, 45 MSc, 10 BSc, working across both Indian and North American locations.
- + 20% projected growth over the next 3 years with a sustained and supported EBITDA to match.
- + Please request the CIM after Fully Executed NDA.

